Table 1.
General description of the study sample.
| Variable | Overall (N = 30) | 2019 (N = 5) | 2020 (N = 9) | 2021 (N = 16) | p1 |
|---|---|---|---|---|---|
| Median age (IQR) | 41 (29–49) | 39 (28–45) | 30 (25–45) | 46 (34–61) | 0.06 |
| Males (N, %) | 20 (66.7) | 2 (40.0) | 5 (55.6) | 13 (81.3) | 0.07 |
| Females (N, %) | 10 (33.3) | 3 (60.0) | 4 (44.4) | 3 (18.8) | |
| Organ system involvement (N, %) | |||||
| Initial clinical focus at diagnosis (N, %) | |||||
| CNS | 8 (26.7) | 2 (40.0) | 2 (22.2) | 4 (25.0) | 0.6 |
| GI | 6 (20.0) | 1 (20.0) | 1 (11.1) | 4 (25.0) | 0.4 |
| MSK | 5 (16.7) | 1 (20.0) | 3 (33.3) | 1 (6.3) | 0.1 |
| Visceral | 7 (23.3) | — | 2 (22.2) | 5 (31.3) | 0.3 |
| Pleuropulmonary | 4 (13.3) | 1 (20.0) | 1 (11.1) | 2 (12.5) | 0.6 |
| Overall involvement | |||||
| CNS | 10 (33.3) | 2 (40.0) | 4 (44.4) | 4 (25.0) | 0.4 |
| GI | 6 (20.0) | 1 (20.0) | 1 (11.1) | 4 (25.0) | 0.7 |
| MSK | 7 (23.3) | 2 (40.0) | 3 (33.3) | 2 (12.5) | 0.2 |
| Visceral | 13 (43.3) | 0 (0.0) | 2 (22.2) | 11 (68.8) | 0.004 |
| Pleuropulmonary | 18 (60.0) | 5 (100) | 2 (22.2) | 11 (68.8) | 0.5 |
| Ganglionic | 19 (63.3) | 2 (40.0) | 6 (66.7) | 11 (68.8) | 0.7 |
| Region of origin (N, %) | |||||
| South Asia | 17 (56.7) | 3 (60.0) | 4 (44.4) | 10 (62.5) | 0.5 |
| North Africa | 5 (16.7) | 1 (20.0) | 2 (22.2) | 2 (12.5) | 0.6 |
| Sub-Saharan Africa | 2 (6.7) | 1 (20.0) | 1 (11.1) | — | 0.2 |
| South America | 1 (3.3) | — | 1 (11.1) | — | 0.5 |
| Spain | 5 (16.7) | — | 1 (11.1) | 4 (25.0) | 0.3 |
| Delay in diagnosis (median, IQR) | |||||
| By months | 6.5 (1.8–30) | 24 (12.5–66) | 4 (1.5–78) | 6 (1.3–11.5) | 0.2 |
| By number of visits | 5 (1–8) | 11 (5–13) | 6 (1–9) | 3 (1–7) | 0.04 |
1
p value comparing 2021 to 2019–2020.